iTeos to Present at Cowen 43rd Annual Health Care Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the Cowen 43rd Annual Health Care Conference being held in Boston, MA on Tuesday, March 7, 2023 at 9:10 a.m. ET.
A live webcast of the presentation will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression, into proof-of-concept trials in several indications following encouraging single-agent activity in Phase 1. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.
For further information, please contact:
Investor Contacts:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contacts:
media@iteostherapeutics.com
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)24.4.2024 10:00:00 CEST | Press release
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritisAlvotech is the first company to publicly announce positive topline results from a patient study evaluating a biosimilar candidate to Simponi or Simponi Aria Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a confirmatory clinical study for AVT05, Alvotech’s proposed biosimilar to Simponi® and Simponi Aria® (golimumab). Alvotech is the first company to announce positive topline results of a clinical trial using a proposed biosimilar to Simponi and Simponi Aria and is one of only two companies known to have initiated such a patient study. “We are delighted at passing yet another clinical milestone in our pipeline,” said Robert Wessman, Chairm
Title correction: EXEL Industries : Second quarter 2023–2024 sales down 1.8%24.4.2024 09:24:17 CEST | Press release
Second quarter 2023-2024 sales: down 1.8% Varying sales performance across activities Q2 sales (January 2024–March 2024) 2022-20232023-2024Change (reported)Change (LFL*) Reported Reported €m % €m % AGRICULTURAL SPRAYING 147.7157.4 +9.7 +6.5% +12.0 +8.1% SUGAR BEET HARVESTERS 34.317.1 -17.2 -50.1% -17.1 -49.9% LEISURE 48.447.4 -1.0 -2.0% -4.4 -9.0% INDUSTRY 67.670.7 +3.1 +4.7% +3.3 +4.9%EXEL Industries Group297.9292.6 -5.3 -1.8% -6.2 -2.1% 6-month sales (October 2023–March 2024) 2022-20232023-2024Change (reported)Change (LFL*) Reported Reported €m % €m % AGRICULTURAL SPRAYING 236.8248.3 +11.6 +4.9% +17.0 +7.2% SUGAR BEET HARVESTERS 53.844.2 -9.6 -17.8% -8.5 -15.9% LEISURE 62.158.5 -3.6 -5.9% -8.8 -14.1% INDUSTRY 130.4141.7 +11.3 +8.7% +14.4 +11.0%EXEL Industries Group483.1492.7 +9.7 +2.0% +14.1 +2.9% * Like-for-like (LFL) = at constant consolidation scope and foreign exchange rates Second quarter 2023-2024 sales The EXEL Industries Group posted revenue of €292.6 million for the second q
Offentliggørelse af prospekt for Investeringsforeningen Danske Invest Select24.4.2024 09:08:50 CEST | pressemeddelelse
Vi skal herved oplyse, at der er foretaget ændringer i prospektet for Investeringsforeningen Danske Invest Select. Opdatering med 2023-tallene i afsnit 10.2 ”Omkostninger til bestyrelsen og Finanstilsynet” samt i tabel 4 ”Administrationsomkostninger de seneste 5 år”.Den årlige opdatering af den forventede indvirkning, som bæredygtighedsrisici kan have på en afdelings afkast (oplyst som "Lav", "Medium" eller "Høj") i afsnit 6 Afdelingernes/andelsklassernes risici.1 andelsklasse er taget ud af prospektet for afdeling US High Yield Bonds.Ændring af de af bestyrelsen fastsatte restriktioner og præciseringer vedrørende investeringerne for en række aktieafdelinger.Opdatering af afsnit 10.7 Porteføljeforvalter. Prospekterne kan fra i dag ses på www.danskeinvest.dk. Med venlig hilsen DANSKE INVEST MANAGEMENT A/S Tina Hjorth Hetting Head of Fund Products
Offentliggørelse af prospekt for Investeringsforeningen Danske Invest24.4.2024 09:06:00 CEST | pressemeddelelse
Vi skal herved oplyse, at der er foretaget ændringer i prospektet for Investeringsforeningen Danske Invest. Opdatering med 2023-tallene i afsnit 10.2 ”Omkostninger til bestyrelsen og Finanstilsynet” samt i tabel 4 ”Administrationsomkostninger de seneste 5 år”.Den årlige opdatering af den forventede indvirkning, som bæredygtighedsrisici kan have på en afdelings afkast (oplyst som "Lav", "Medium" eller "Høj") i afsnit 6 Afdelingernes/andelsklassernes risici.13 andelsklasser, primært NOK W klasser er taget ud af prospektet.Ændring af de af bestyrelsen fastsatte restriktioner og præciseringer vedrørende investeringerne for en række aktieafdelinger.Præcisering af hvorledes valutaafdækningen foretages for alle Global Ansvarlig Portefølje afdelingerne.Opdatering af afsnit 10.7 Porteføljeforvalter. Prospekterne kan fra i dag ses på www.danskeinvest.dk. Med venlig hilsen DANSKE INVEST MANAGEMENT A/S Tina Hjorth Hetting Head of Fund Products
Consensus estimates ahead of Q1 202424.4.2024 09:04:00 CEST | Press release
Alm. Brand Group has published consensus estimates prior to the announcement of the Q1 results. Consensus estimates are also available via: almbrand.dk Conference Call Alm. Brand Group will report its Q1 2024 results on May 2 and host a conference call with management at 11:00 CET on the day of release. Dial in for analysts and investors (pincode: 978854) : Denmark: +45 8987 5045 UK: +44 20 3936 2999 USA: +1 646 664 1960 Contact Please direct any questions regarding this announcement to: Investors and equity analysts: Mads Thinggaard - Head of IR, Rating & ESG Reporting - mobile no. +45 2025 5469 Press: Mikkel Lars Nikolajsen - Head of Media Relations - mobile no. +45 2218 5711 Attachments Consensus ahead of Q1 2024Investor news_Consensus Q1 2024